The Evolving Role of BTKi’s in CLL
Tuesday, June 28, 2022
10 AM PT / 11 PM MT / 12 PM CT / 1 PM ET (Duration 60 minutes)
Description:
The targeted therapy Bruton tyrosine kinase inhibitors (BTKi’s) have come a long way since revolutionizing CLL treatment with the arrival of ibrutinib. There are now other BTKi options such as acalabrutinib, zanubrutinib, and the next generation non-covalent BTK Inhibitor, pirtobrutinib. Join CLL Society and Dr. Matthew Davids from Dana Farber Cancer Institute to take a deep dive into different BTKi’s, how they work, how they compare to each other and other treatment options, potential side effects, and the future role of these therapies.
Speaker:
Moderator:
Brian Koffman, MDCM (retired), MS Ed
Co-Founder, Executive Vice President, and Chief Medical Officer
CLL Society
Speaker:
Matthew S. Davids, MD, MMSc
Associate Director, Center for Chronic Lymphocytic Leukemia
Dana Farber Cancer Institute
This program was made possible by grant support from AstraZeneca, BeiGene, Pharmacyclics, and Janssen.
